Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®

An Observational Study Evaluating the Safety and Efficacy of the Treatment With Biphasic Insulin Aspart (NovoMix® 30 FlexPen®) in the Treatment of Type 2 Diabetics After Failing on Basal/ Intermediate Mono or Combination Therapy

This study is conducted in Africa. The aim of this observational study is to evaluate the incidence of adverse events while using NovoMix® 30 FlexPen® under normal clinical practice conditions.

Inclusion Criteria:

• Type 2 diabetes having failed on basal insulin with or without OAD
• HbA1c greater than 7.0%

Exclusion Criteria:

• Subjects being unlikely to comply with protocol requirements
• Subjects who previously enrolled in this study
• Subjects with hypersensitivity to biphasic insulin aspart or any of the excipients
• Women who are pregnant, breast feeding and women in child bearing capacity who are not using reliable contraceptive method